Vitamin D and Autoimmune Disease: What Does the Science Actually Show?

This is where the answer becomes disease-specific.

Autoimmune diseases are not one single biological condition. Multiple sclerosis, Hashimoto’s thyroiditis, Crohn’s disease, lupus and rheumatoid arthritis involve different tissues, immune pathways, treatments and clinical outcomes.

It is therefore unlikely that one vitamin D strategy will produce the same result across every autoimmune disease.

Randomized trials and meta-analyses nevertheless provide several interesting signals.

Hashimoto’s thyroiditis

Randomized trials and subsequent meta-analyses have produced an interesting signal in Hashimoto’s thyroiditis.

A meta-analysis of 12 randomized studies involving 862 participants found significant reductions in both anti-thyroid peroxidase antibodies, or anti-TPO, and anti-thyroglobulin antibodies following vitamin D supplementation. The analysis also reported changes in several thyroid-function measures.

This supports the possibility that vitamin D supplementation can influence biological markers of Hashimoto’s thyroiditis rather than merely correcting an unrelated nutritional deficiency.

The longer-term clinical meaning still needs to be distinguished from the laboratory effect.

Reduced antibody concentrations do not by themselves establish reversal of Hashimoto’s, and questions remain about the extent to which supplementation changes symptoms, long-term thyroid function, disease progression or the need for thyroid hormone replacement.

For someone with Hashimoto’s and low vitamin D status, however, vitamin D deserves genuine clinical attention within the broader treatment picture.

Rheumatoid arthritis

Vitamin D deficiency is frequently reported in rheumatoid arthritis, and supplementation has been investigated as a possible adjunct to established treatment.

A systematic review and meta-analysis of randomized controlled trials involving more than 3,000 participants found a mixed but interesting picture.

Vitamin D supplementation did not significantly improve every inflammatory or clinical measure. Overall effects on CRP, ESR and some conventional disease-activity analyses were not significant.

However, pooled analyses did find improvements in pain and in some DAS28 disease-activity measures, while responses varied considerably between studies.

This heterogeneity matters. Trials differed in vitamin D dose, baseline vitamin D status, duration, patient characteristics and concurrent rheumatoid arthritis treatment.

The evidence therefore does not support vitamin D as a replacement for disease-modifying antirheumatic treatment.

It does support taking vitamin D status seriously and continuing to investigate whether supplementation provides additional benefit in particular groups of patients.

Inflammatory bowel disease and Crohn’s disease

Vitamin D deserves particular attention in inflammatory bowel disease for more than one reason.

Crohn’s disease and ulcerative colitis can affect nutritional status, while intestinal inflammation or surgery can impair nutrient absorption. Corticosteroid exposure and chronic inflammation can also increase concerns about bone health.

Vitamin D status is therefore clinically relevant even before considering whether supplementation directly influences intestinal inflammation.

Research suggests there may also be an effect on disease course.

A systematic review and meta-analysis of randomized trials found that vitamin D supplementation was associated with a lower risk of clinical relapse in inflammatory bowel disease. Across the pooled analysis, the relative risk of relapse was 0.64.

The signal was particularly interesting in Crohn’s disease.

Among patients with Crohn’s disease in clinical remission, supplementation was associated with a relative risk of relapse of 0.47.

The evidence for ulcerative colitis was much less certain because substantially fewer patients were represented.

This makes vitamin D particularly interesting in Crohn’s disease because several issues intersect: intestinal inflammation and absorption, nutritional status, bone health and the possibility of an additional effect on disease course.

These findings do not make vitamin D a substitute for gastroenterological treatment, but they provide a stronger clinical rationale than simply correcting an incidental laboratory deficiency.

Systemic lupus erythematosus

People with systemic lupus erythematosus often have low vitamin D levels.

Sun avoidance, which can be medically necessary because ultraviolet exposure can trigger disease activity in photosensitive patients, can further contribute.

Recent systematic reviews and meta-analyses suggest that vitamin D supplementation can produce modest improvements in measures of lupus disease activity and some immunological outcomes.

Not every clinical or laboratory endpoint improves consistently, but the evidence is increasingly difficult to summarise simply as no effect.

A more accurate conclusion is that vitamin D appears to have potential as an adjunctive factor in lupus management, particularly when vitamin D status is low, while the magnitude and clinical importance of the effect differ between outcomes and studies.

Multiple sclerosis: why recent evidence is especially interesting

The relationship between vitamin D and multiple sclerosis has been studied extensively.

Geographical patterns, sun exposure, vitamin D status and MS risk have long suggested a connection.

Yet clinical trials investigating vitamin D as an add-on treatment in established MS have generally produced limited or inconsistent improvements in major clinical outcomes.

Then an important randomized trial changed the discussion.

The French D-Lay MS randomized clinical trial, published in JAMA in 2025, investigated high-dose cholecalciferol in people with a recent clinically isolated syndrome typical of multiple sclerosis.

A total of 316 participants were randomized, with 303 included in the primary analysis.

Participants received 100,000 IU of vitamin D3 every two weeks or placebo for up to 24 months.

The primary outcome combined clinical relapse with MRI evidence of disease activity.

Disease activity occurred in 60.3% of participants receiving vitamin D compared with 74.1% in the placebo group, corresponding to a hazard ratio of 0.66.

MRI findings were particularly notable. MRI disease activity, new lesions and contrast-enhancing lesions significantly favoured vitamin D.

The clinical outcomes require a more precise interpretation.

Relapses alone were not significantly reduced, and the trial did not find significant differences in disability, fatigue, quality of life, depression or anxiety.

This makes D-Lay important without making it a universal argument for high-dose vitamin D.

It provides randomized evidence that high-dose vitamin D influenced disease activity, particularly MRI activity, when introduced very early in the MS disease process.

It also raises an important research question: could timing and disease stage partly explain why intervention very early in MS produced a stronger signal than many studies in established disease?

The study does not establish that everyone with multiple sclerosis should take 100,000 IU every two weeks, and the regimen should not be extrapolated into self-treatment.

Vitamin D research can appear contradictory because studies are not always asking the same question.

Results can depend on:

• the autoimmune disease being studied

• whether disease is early or established

• baseline vitamin D status

• dose and dosing interval

• duration of supplementation

• absorption

• body composition

• other treatments

• the clinical outcome being measured

Giving vitamin D to someone with a substantial deficiency is biologically different from giving additional vitamin D to someone whose status is already adequate.

Preventing autoimmune disease is also different from reducing disease activity after autoimmunity has already developed.

This is why one general question such as “Does vitamin D work for autoimmune disease?” is less useful than identifying the specific clinical question being asked.

The usual blood test for vitamin D status is:

25-hydroxyvitamin D, or 25(OH)D.

This is the principal circulating marker used to assess vitamin D status.

The biologically active form, 1,25-dihydroxyvitamin D, answers a different physiological question and is generally not the appropriate routine marker for assessing vitamin D stores.

Its concentration is tightly regulated and can remain normal, or sometimes increase, even when vitamin D reserves are low.

This distinction matters because ordering a more sophisticated-sounding test does not necessarily provide more useful information.

The test should match the clinical question.

In someone with autoimmune or chronic inflammatory disease, testing can become particularly relevant when there are factors such as:

• previously documented deficiency

• limited sun exposure

• gastrointestinal disease or malabsorption

• restrictive diet

• osteoporosis or increased fracture risk

• medications affecting vitamin D or bone metabolism

• repeated nutritional deficiencies

• a clinical reason to investigate micronutrient status more closely

At Centre Algos, vitamin D can be assessed as part of a broader targeted biological evaluation when the patient’s condition, symptoms, diet, gastrointestinal function, medication or previous blood results make it clinically relevant.

There is no universally established 25(OH)D target that has been shown to be optimal across all autoimmune diseases.

This is particularly important because online recommendations often propose specific high targets for people with autoimmunity.

Current clinical guidance has moved away from claiming that one concentration defines an optimal level for disease prevention in otherwise healthy people.

The 2024 Endocrine Society guideline concluded that clinical-trial evidence was insufficient to establish universal 25(OH)D thresholds linked to specific disease-prevention benefits.

That does not make vitamin D testing irrelevant in clinical practice.

It means the reason for testing matters.

Someone with inflammatory bowel disease and possible malabsorption, for example, presents a different clinical question from an otherwise healthy person requesting routine vitamin D screening.

At Centre Algos, we therefore interpret vitamin D in context rather than pursuing one universal autoimmune target.

Relevant factors can include the autoimmune condition, previous results, nutritional status, gastrointestinal absorption, bone health, medication, supplementation, sun exposure and the reason the test was ordered.

The objective is to use the result to answer a clinical question, not simply to push the number as high as possible.

This distinction is fundamental.

If someone has vitamin D deficiency, correcting it has an established nutritional and skeletal rationale.

If someone with an autoimmune disease also has vitamin D deficiency, correcting that deficiency can form part of their overall care.

Prevention is another question. VITAL investigated whether vitamin D influenced the development of new autoimmune disease.

Using vitamin D specifically to modify the activity of an established autoimmune disease is a third therapeutic question.

Disease-specific trials such as D-Lay, and studies in Hashimoto’s thyroiditis or inflammatory bowel disease, address this question.

These three situations require different evidence and potentially different treatment strategies.

This is particularly important because online discussions can move directly from:

Vitamin D is important for immune function

to:

Therefore high-dose vitamin D treats autoimmune disease.

The second statement does not automatically follow from the first.

At the same time, the disease-specific research shows that therapeutic effects should not simply be dismissed. The evidence needs to be interpreted according to the condition and the context in which it was produced.

Vitamin D is fat-soluble, which means excessive intake can accumulate and cause toxicity.

For adults, the European Food Safety Authority sets the tolerable upper intake level at 100 micrograms per day, equivalent to 4,000 IU of vitamin D per day, for chronic intake from all dietary sources.

A tolerable upper intake level is a population-level safety threshold.

It is not the same thing as an absolute medical treatment ceiling.

Clinical studies sometimes use higher doses for defined indications and under structured supervision. D-Lay MS, for example, used 100,000 IU every two weeks within a randomized clinical trial.

The distinction is therefore not simply “below 4,000 IU safe, above 4,000 IU dangerous.”

The relevant questions include dose, duration, clinical indication, calcium metabolism, kidney function, other supplementation and the level of monitoring.

Excessive vitamin D can lead to excessive calcium absorption and potentially cause:

• hypercalcaemia

• hypercalciuria

• kidney stones or kidney injury

• soft-tissue calcification

• nausea

• weakness

• neurological symptoms

• cardiac rhythm disturbances in severe toxicity

Very high doses should not be treated as ordinary nutritional supplementation.

The Coimbra Protocol is a medically supervised approach that uses very high doses of vitamin D in people with autoimmune diseases.

It is fundamentally different from ordinary vitamin D supplementation.

A published retrospective study followed 319 patients with different autoimmune diseases treated according to the protocol.

The mean vitamin D3 dose was approximately 35,000 IU per day, with substantial variation between patients.

Treatment included a low-calcium diet, high fluid intake and repeated monitoring of calcium metabolism and kidney function.

The investigators reported that mean calcium and renal-function measurements remained within normal ranges under this structured supervision.

This is relevant safety information because it demonstrates that very high-dose vitamin D has been used in a monitored clinical setting.

But the study was designed primarily to evaluate safety parameters, not to establish therapeutic efficacy against autoimmune disease.

It was retrospective, had no randomized placebo comparison and did not provide controlled evidence that the protocol improves the underlying autoimmune conditions.

That distinction is important.

The Coimbra Protocol should therefore not be treated as equivalent to:

• ordinary correction of vitamin D deficiency

• conventional vitamin D supplementation

• a disease-specific high-dose regimen tested in a randomized clinical trial such as D-Lay MS

All involve vitamin D, but their doses, objectives, monitoring and level of supporting evidence are different.

People considering very-high-dose vitamin D should not reproduce these protocols themselves. At these doses, calcium metabolism and kidney function become clinically important and structured medical monitoring is essential.

Vitamin D can be produced in the skin following ultraviolet B exposure.

It can also be obtained from foods, particularly fatty fish, egg yolk and certain fortified foods, although diet alone often provides relatively modest amounts.

In Switzerland and other countries at northern latitudes, vitamin D production from sunlight varies considerably by season.

Age, skin pigmentation, clothing, time spent outdoors and sun-protection practices also influence production.

For someone with low vitamin D status, supplementation may therefore be appropriate depending on the degree of deficiency and clinical context.

This should be considered alongside diet, lifestyle, absorption and medical history rather than treating supplementation as an isolated intervention.

At Centre Algos, vitamin D is considered within the wider clinical picture rather than as an isolated laboratory number.

When relevant, we review:

• the autoimmune or inflammatory condition

• current symptoms and disease history

• previous laboratory results

• diet and supplementation

• gastrointestinal symptoms and possible absorption problems

• medications

• sun exposure and lifestyle

• bone-health considerations

• other nutritional or metabolic factors that may be relevant

Vitamin D can then be measured through 25(OH)D testing when clinically appropriate.

Depending on the individual situation, this can form part of a broader Functional Biology & Micronutrition assessment, including other targeted blood investigations where there is a clinical reason to investigate further.

If a deficiency or another relevant imbalance is identified, we discuss how it fits into the wider treatment plan rather than treating a single laboratory value in isolation.

For people already receiving specialist treatment for an autoimmune disease, this approach can sit alongside that care.

The objective is to identify modifiable nutritional, metabolic and lifestyle factors that can be addressed within the broader treatment strategy.

Autoimmune diseases can affect the nervous system, joints, gastrointestinal tract, thyroid, kidneys, lungs, skin and other organs.

New or rapidly worsening symptoms therefore require appropriate medical assessment.

This is particularly important with symptoms such as:

• new neurological weakness, loss of vision or major sensory change

• severe or rapidly worsening joint swelling

• significant gastrointestinal bleeding

• persistent high fever

• unexplained major weight loss

• severe dehydration

• chest pain or difficulty breathing

• signs of kidney involvement

• rapidly changing thyroid symptoms

• a significant deterioration in a known autoimmune disease

Vitamin D or micronutritional assessment should not delay evaluation of potentially serious disease activity.

Vitamin D and autoimmunity have a genuine scientific relationship.

Vitamin D participates in immune regulation. Low vitamin D levels are frequently found in several autoimmune diseases.

Large randomized evidence from VITAL suggests supplementation can reduce the development of new autoimmune disease in some populations.

Disease-specific randomized trials and meta-analyses also provide interesting evidence in Hashimoto’s thyroiditis, inflammatory bowel disease, lupus, rheumatoid arthritis and early multiple sclerosis.

But those findings do not all answer the same question.

Preventing disease, correcting deficiency and using vitamin D as an adjunctive therapeutic intervention are separate clinical questions.

The most useful approach is therefore not to assume that every autoimmune disease requires high-dose vitamin D.

It is to understand the individual condition, assess vitamin D when clinically relevant, correct genuine deficiencies and interpret therapeutic evidence in the context in which it was actually produced.

Can vitamin D prevent autoimmune disease?

The VITAL randomized trial found fewer new confirmed autoimmune diseases among participants assigned to 2,000 IU of vitamin D3 per day, corresponding to approximately a 22% reduction during the randomized follow-up period. This is evidence for a preventive effect in the population studied, not proof that vitamin D prevents every autoimmune disease in every person.

Can vitamin D treat an autoimmune disease?

Vitamin D may have useful adjunctive effects in some autoimmune conditions, but the evidence differs considerably by disease. Results in Hashimoto’s thyroiditis, Crohn’s disease, lupus and early multiple sclerosis are among the areas of particular interest. Vitamin D should not be treated as one universal autoimmune therapy.

Should people with autoimmune disease test their vitamin D?

Testing can be useful when there is a clinical reason, particularly with known deficiency, limited sun exposure, malabsorption, gastrointestinal disease, bone-health concerns, certain medications or other nutritional risk factors. The appropriate decision depends on the individual situation.

Which blood test measures vitamin D?

The usual test is serum 25-hydroxyvitamin D, or 25(OH)D. The active hormone 1,25-dihydroxyvitamin D is generally not the correct routine test for assessing vitamin D stores.

What vitamin D level is considered deficient?

Definitions vary somewhat between clinical organisations and according to context. The result should be interpreted alongside the reason for testing, bone health, nutritional status, absorption, medication and the patient’s wider clinical picture.

Is there an optimal vitamin D level for autoimmune disease?

No universal 25(OH)D level has been established as optimal for every autoimmune disease. Claims that all autoimmune patients should maintain one specific high concentration go beyond the available evidence.

Does vitamin D help Hashimoto’s thyroiditis?

Randomized studies and meta-analyses suggest vitamin D supplementation can reduce anti-TPO and anti-thyroglobulin antibody concentrations. Some thyroid-function measures have also changed in studies, although the long-term clinical consequences remain less clear.

Does vitamin D help multiple sclerosis?

The answer partly depends on disease stage. Earlier studies in established MS produced mixed results. The 2025 D-Lay MS randomized trial found significantly less combined disease activity, particularly MRI activity, in people treated very early after a clinically isolated syndrome. Relapses alone, disability and fatigue were not significantly improved.

Can vitamin D help Crohn’s disease?

Vitamin D deficiency is particularly relevant in Crohn’s disease because intestinal inflammation and malabsorption can affect nutritional status and bone health. A randomized-trial meta-analysis also found a lower risk of clinical relapse, with a particularly interesting signal in Crohn’s disease in remission.

Is 4,000 IU the maximum safe vitamin D dose?

EFSA’s tolerable upper intake level for adults is 4,000 IU per day for chronic intake from all sources. This is a population safety threshold, not an absolute medical treatment ceiling. Higher doses can be used in specific medical circumstances under appropriate supervision.

Is high-dose vitamin D safe?

High doses can be used medically in certain circumstances, but they require a different level of clinical justification and monitoring. Excessive vitamin D can cause hypercalcaemia, hypercalciuria, kidney complications and other forms of toxicity.

What is the Coimbra Protocol?

The Coimbra Protocol is a medically supervised strategy using very high doses of vitamin D for autoimmune disease. Published observational safety data exist, but robust randomized evidence demonstrating broad therapeutic effectiveness remains limited. It should not be confused with routine vitamin D supplementation or ordinary deficiency correction.

If you live with an autoimmune or chronic inflammatory condition and want to understand whether vitamin D, micronutrient status, digestion or other modifiable factors could be relevant, a consultation at Centre Algos allows us to review the wider clinical picture.

We can review your symptoms, medical history, existing blood results, nutrition, supplementation and current treatment, then discuss whether targeted additional testing or changes to your treatment plan are appropriate.

• Hahn J, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452
• Vitamin D supplementation in Hashimoto thyroiditis: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023
• Vitamin D supplementation in rheumatoid arthritis: a systematic review and meta-analysis. Nutrition Reviews. 2024
• Vitamin D supplementation and clinical relapse in inflammatory bowel disease: a meta-analysis of randomized controlled trials. Inflammatory Bowel Diseases. 2024
• High-dose vitamin D in clinically isolated syndrome typical of multiple sclerosis: the D-Lay MS randomized clinical trial. JAMA. 2025
• Vitamin D in systemic lupus erythematosus. Autoimmunity Reviews. 2026
• Coimbra protocol: high-dose vitamin D in autoimmune disease, published safety data. Nutrients. 2022
• NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals
• EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for vitamin D. EFSA Journal. 2023
• Demay MB, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947

• Autoimmune & Inflammatory Conditions
• Autoimmune Disease and Diet: What Role Do Gut Health, the Microbiome and Micronutrients Play?
• Functional Biology & Micronutrition
• Fatigue & Brain Fog